[{"id":"a08199e1-d4ac-4363-90a1-41a28d158504","acronym":"UT-201501;ATTCK-20-2t","url":"https://clinicaltrials.gov/study/NCT02776813","created_at":"2021-01-18T13:36:59.779Z","updated_at":"2024-07-02T16:36:47.201Z","phase":"Phase 1","brief_title":"Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma","source_id_and_acronym":"NCT02776813 - UT-201501;ATTCK-20-2t","lead_sponsor":"Cogent Biosciences, Inc.","biomarkers":" CCND1","pipe":" | ","alterations":" CCND1 expression","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • ACTR087"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 02/12/2020","primary_completion_date":" 02/12/2020","study_txt":" Completion: 02/12/2020","study_completion_date":" 02/12/2020","last_update_posted":"2020-03-31"}]